Todos os estudos
RecrutamentoExploratório terapêutico (Fase II)Intervencionista

Multicentre Randomized trial of Ghrelin in anterior circulation ischemic stroke treated with endovascular thrombectomy. A randomized phase 2 trial.

An ischaemic stroke happens when a blood clot blocks blood flow to part of the brain. Doctors often treat this quickly by removing the clot through a procedure called a thrombectomy. While this treatment saves lives, brain tissue can still suffer damage. This early-stage clinical trial is investigating a drug called acyl-ghrelin. Ghrelin is a naturally occurring hormone in the body that may help protect brain cells and reduce swelling after an injury. In this study, patients receiving standard clot-removal treatment will also receive either ghrelin or a dummy medicine (placebo). Doctors will check their recovery over the first week in hospital using scans and physical tests. A follow-up phone call at three months will check memory, daily activities, and general recovery to see if the treatment helps people bounce back better.

Em resumo

Status
Recrutamento
Fase
Exploratório terapêutico (Fase II)
Patrocinador
Rijnstate Ziekenhuis Stichting
Meta de inscrição
80
Iniciar
15 Out 2024

Sobre o que é este estudo?

Every year, thousands of people in the UK have an ischaemic stroke, where a blood clot suddenly cuts off the blood supply to part of the brain. When brain cells are starved of oxygen, they quickly become damaged or die. In many hospitals, doctors use an emergency procedure called a thrombectomy to physically fish out the clot and restore blood flow. Even when this procedure goes well, the brain often needs extra support to heal.

Researchers are testing whether an experimental medicine called acyl-ghrelin can help protect brain tissue during this critical recovery window. Ghrelin is a hormone our bodies naturally produce, known for stimulating appetite and reducing inflammation. Scientists believe giving an extra dose shortly after a stroke may calm down inflammation, protect fragile brain cells, and improve long-term healing.

In this study, doctors will closely monitor patients while they are in hospital. They will track blood pressure, body temperature, blood sugar levels, and perform a brain scan (MRI) after three days to measure the size of any remaining brain injury. They will also assess stroke symptoms after one week.

Finding new ways to protect the brain alongside clot-removal treatments is vital. If successful, this trial could open the door to larger studies, bringing us closer to better treatments that reduce long-term disability for stroke survivors.

Pontos principais

  • Tests whether the hormone ghrelin can protect brain tissue after an ischaemic stroke.
  • Open to adults having emergency clot-removal treatment (thrombectomy).
  • Given alongside standard hospital stroke care, without delaying emergency treatment.
  • Includes daily health checks in hospital, an MRI scan at day three, and a phone check at three months.
  • Participation is entirely voluntary and does not affect your standard NHS care.

Quem pode ser elegível?

This trial is open to adults aged 18 and over who have recently suffered an acute ischaemic stroke in the main blood vessels supplying the front of the brain. To be considered, patients must be scheduled to have, or have just had, emergency clot-removal treatment (a thrombectomy).

Because this is an emergency trial started in hospital shortly after a stroke occurs, doctors assess eligibility right away in the emergency or stroke unit. Both men and women of any adult age can take part if they meet the medical criteria.

People whose stroke was caused by bleeding in the brain (a haemorrhagic stroke) or who cannot safely receive emergency clot-removal treatment will not be able to join. The hospital stroke team will review each patient's medical history, current scans, and safety tests before enrolling them.

Este estudo pode ser adequado para você?

Responda a estas perguntas rápidas para ver se você pode ser elegível. Este é apenas um guia — a decisão final é da equipe de pesquisa.

  1. I am aged 18 or older.
  2. I have had an ischaemic stroke (a stroke caused by a blocked blood vessel).
  3. The stroke affected the front circulation of my brain.
  4. I am receiving emergency clot-removal treatment (thrombectomy) in hospital.
  5. I or my representative am willing to take part in follow-up checks for 90 days.
Responda a todas as perguntas para ver o seu resultado.

O que envolve a participação?

Because stroke is a medical emergency, taking part begins in the hospital. Participants will receive the trial medication through a drip into a vein alongside their normal emergency stroke care. Half of the participants will receive ghrelin, while the other half will receive standard care with a placebo (a harmless dummy treatment).

While in hospital, the clinical team will closely track your recovery. For the first week (or until you go home), nurses will check your temperature, blood pressure, and blood sugar levels daily. You will have brain scans (an MRI) around three days after the stroke to see how your brain is healing, as well as regular standard physical checks to measure your stroke symptoms.

Your formal hospital checks for the study are completed around day seven or when you are discharged. About three months (90 days) later, a researcher will contact you or your family by telephone. They will ask questions about your memory, thinking, and how well you can carry out everyday tasks at home. In total, your participation lasts about three months.

Riscos e benefícios potenciais

A potential benefit of taking part is that the treatment might help protect your brain cells and improve your recovery, although this cannot be guaranteed as ghrelin is still being tested. You will also receive very close health monitoring by a specialist hospital team. However, all new medicines carry potential risks, including unexpected side effects or allergic reactions. The research team watches participants very closely to manage any issues immediately. Taking part is completely voluntary. If you or your family choose not to join, or decide to leave the trial at any point, your normal NHS care and clot-removal treatment will continue unaffected.

Localizações (1)

Algumas localizações dos sites são aproximadas. Estamos melhorando isso — por favor, verifique com a equipe de teste antes de viajar.
  • —
    Não verificado
    Países Baixos

Perguntas frequentes

What is ghrelin?

Ghrelin is a natural hormone made mainly in the stomach. In the body, it controls hunger, but scientists have found it can also calm inflammation and protect cells from damage.

Will taking part delay my emergency stroke treatment?

No. Emergency clot removal (thrombectomy) is life-saving and is never delayed for this trial. The study treatment is given alongside your standard emergency care.

Do I have to travel for extra hospital visits?

Most study checks happen while you are already staying on the stroke ward. The final check-up at three months is done over the telephone, so you do not need to make an extra journey.

What happens if I cannot give consent because of my stroke?

In emergency stroke research, strict legal and ethical rules allow doctors to speak with a family member or legal representative to discuss joining on your behalf until you can make decisions yourself.

Will I definitely receive the study drug?

Not necessarily. This is a randomised trial, meaning a computer system randomly decides whether you receive the active medicine (ghrelin) or a dummy treatment (placebo).

Como saber mais

Sempre consulte seu médico ou especialista antes de decidir participar de um estudo.

Interessado em participar?

Registre seu interesse

Compartilhe seus detalhes e a equipe de pesquisa para "Multicentre Randomized trial of Ghrelin in anterior circulat…" entrará em contato com você se você for elegível. Sempre fale com seu médico antes de concordar em participar.

Discussão

Discussão da comunidade

Desenvolvido pelo nosso fórum em community.patient.info. Por favor, seja respeitoso — isto não é um conselho médico.